L-Tartrate

• L-carnitine itself is a naturally occurring molecule in animals and humans, synthesized from lysine and methionine.
• The salt form L-Carnitine L-Tartrate (LCLT) is synthetically prepared. In supplement form, LCLT is widely used in sports nutrition for enhancing exercise recovery, reducing muscle damage, and fatigue.
• Regulatory assessments (e.g., by EFSA) consider LCLT a safe source of L-carnitine in foods/supplements up to certain daily limits

• Molecular formula: It is a salt composed of L-carnitine and L-tartaric acid.
• L-carnitine: a quaternary ammonium compound that is biologically active, involved in transporting long-chain fatty acids into mitochondria.
• L-Tartrate: the deprotonated form (salt) of L-tartaric acid, which itself is a dicarboxylic acid and has antioxidant properties.
• Physical properties: according to chemical sources, LCLT is a white crystalline powder, stable, with good solubility in water, and less hygroscopic than free L-carnitine, which makes it more suitable for tablet/capsule forms.

• Fatty Acid Shuttling: L-carnitine, the biologically active component, facilitates the transport of long-chain fatty acids into the mitochondria for β-oxidation and ATP (energy) production.
• Antioxidant Action: The tartrate moiety (L-tartaric acid) has antioxidant properties. As per NCI Drug Dictionary, LCLT may exert “antioxidant activities.” Supplementation has been shown to increase levels of superoxide dismutase (SOD), a key antioxidant enzyme.
• Reduction of Purine Catabolism & Free Radical Formation: Studies in exercise contexts show that LCLT reduces markers of purine catabolism (e.g., hypoxanthine, xanthine oxidase) and lowers oxidative stress (e.g., malondialdehyde) after strenuous exercise.
• Muscle Tissue Protection: LCLT reduces exercise-induced muscle disruption (e.g., lower creatine kinase, myoglobin) and speeds recovery.
• Hormonal Effects (Recovery): In a resistance-exercise study, LCLT increased IGFBP-3 (insulin-like growth factor binding protein-3) post-exercise, which may reflect better preservation of muscle tissue / higher capacity for repair.

1. Improved Exercise Recovery & Reduced Muscle Damage: A randomized, double-blind, placebo-controlled trial (80 participants, 5 weeks) found that LCLT (daily supplementation) improved perceived recovery, reduced muscle soreness, and lowered serum creatine kinase (CK) compared to placebo. In the same study, after a high-volume exercise challenge, LCLT helped blunt declines in strength and power.
2. Reduced Oxidative Stress: LCLT supplementation increased serum superoxide dismutase (SOD) in that 5-week study, indicating enhanced antioxidant defenses.
3. Attenuation of Biochemical Markers of Exercise-Induced Damage In a crossover study (3 weeks supplementation, 2g/day L-carnitine), LCLT significantly reduced blood markers after resistance exercise: hypoxanthine, xanthine oxidase (purine catabolism), malondialdehyde (lipid peroxidation), myoglobin, creatine kinase, etc. Another older study (10 trained men) showed LCLT reduced the increase in malondialdehyde and other damage markers after squats, compared to placebo.
4. Hormonal / Growth Factor Modulation: As noted, LCLT increased IGFBP-3 after resistance exercise, which may be beneficial for recovery.
5. Safety Profile in Healthy Individuals: In a 3-week human study, 3 g/day of LCLT in healthy active men had no significant changes in complete blood count, liver enzymes, renal markers, electrolytes, etc. Risk assessments conclude that up to 3 g/day of LCLT (which corresponds to ~2 g/day L-carnitine) is unlikely to cause adverse effects in healthy adults, provided tartaric acid intake from all sources remains within acceptable limits.
6. Regulatory / Safety Approvals: According to a GRAS (Generally Recognized as Safe) notification, EFSA (European Food Safety Authority) considers LCLT safe when used as a source of L-carnitine, within exposure limits. Food Standards assessments also reflect this: e.g., in an Australian food-standards code application, it is noted that “consumption of up to 3 g/day of L-carnitine L-tartrate … presents no safety concerns” under defined conditions.

• People with kidney disease: risk assessments highlight caution because L-carnitine is renally excreted, and impaired kidney function may change its dynamics.
• Those with high plasma TMAO (trimethylamine-N-oxide) levels might be at risk: some data suggest high carnitine intake can increase TMAO, which has been associated with adverse cardiovascular outcomes in certain populations.
• Individuals with inborn errors of metabolism involving carnitine: risk assessment warns of potential adverse effects.
• Children: according to some assessments, in children (especially younger ones), high-dose LCLT may pose risks; risk characterisation assumed adult tolerance but flagged limited data.
• Tartaric acid intake: because LCLT contributes tartaric acid, total dietary tartaric acid intake (from other sources) should not regularly exceed acceptable levels

• Based on available research and reports: In controlled clinical safety study (3 g/day, 3 weeks): no significant adverse effects in metabolic, hematologic parameters.
• Some commonly reported tolerability issues (from supplement-user anecdotal reports) include: Fishy body odor, especially at higher doses.
• Gastrointestinal discomfort: nausea, cramping, diarrhea noted in some anecdotal doses. Possible joint discomfort: in some user reports, hip/joint pain was linked to LCLT supplementation.
• Long-term risk related to TMAO: as mentioned above, higher L-carnitine intake may lead to increased TMAO production via gut microbiota, which is speculated (but not definitively proven) to increase cardiovascular risk in certain contexts

• Drugs affecting renal function: Because carnitine is renally excreted, drugs that impair kidney function may alter its clearance (hypothetical risk).
• Drugs affecting metabolism / methylation / amine metabolism: As L-carnitine is a quaternary amine, interactions with drugs that influence amine metabolism (though specific high-quality studies are limited).
• Gut microbiome modulators: Since unabsorbed L-carnitine may be metabolized by gut flora to TMA (then TMAO), coadministration with probiotics, or compounds that modify gut flora, might influence TMAO production (theoretical).
• Antioxidant supplements / adaptogens: Co-supplementation with other antioxidants (e.g., vitamin C, polyphenols) may have additive effects on reducing oxidative stress, but high-dose combined antioxidant therapy should be approached with caution (no large trials specifically combining LCLT with adaptogens like ashwagandha or Rhodiola, to my knowledge).
• Exercise / performance supplements: In sports nutrition, LCLT is often combined with other performance enhancers (e.g., creatine, beta-alanine); while some practitioners use them together, formal drug–drug interaction studies are limited, so caution and incremental dosing are pragmatic.

• Reducing muscle damage: https://pubmed.ncbi.nlm.nih.gov/18545197/
• Lowering oxidative stress: https://pmc.ncbi.nlm.nih.gov/articles/PMC7843735/
• Improving subjective recovery/fatigue: https://pmc.ncbi.nlm.nih.gov/articles/PMC8541253/

L-Carnitine L-Tartrate (LCLT) is a well-studied supplement form of L-carnitine, with evidence from human trials supporting its use for improving exercise recovery, reducing muscle damage markers (CK, myoglobin), lowering oxidative stress, and improving subjective recovery/fatigue. It is reasonably safe in healthy individuals when used in moderate doses (e.g., up to ~ 3 g/day LCLT, which corresponds to ~2 g/day L-carnitine), with minimal adverse effects in controlled studies. However, caution is warranted in specific populations (kidney disease, metabolic disorders), as well as in considering total dietary exposure to tartaric acid. The potential for increased TMAO production (via gut microbiota) and its longer-term cardiovascular implications is a theoretical concern, though not conclusively proven in healthy individuals. There is limited but plausible potential for interactions with other supplements, especially those affecting antioxidant status or gut microbiota, but robust drug–drug interaction data are lacking.